Novus Acquisition and Development Corp., operating as Novus Cannabis MedPlan, reported significant financial growth during the first nine months of 2025, demonstrating the viability of its ancillary healthcare approach to cannabis benefits. The company, which trades on the OTC Markets under the symbol NDEV, achieved an 18.1% increase in EBITDA to $152,572 while growing revenue by 8.85% to $300,044 compared to the same period in 2024.
The financial performance reflects Novus's strategic positioning as a non-plant-touching business that does not directly grow, process, or sell cannabis. Instead, the company operates as a health plan carrier specializing in proprietary prescription drug programs that include cannabis benefits. This model allowed Novus to maintain a strengthened balance sheet with cash and equivalents increasing 7.2% to $235,782 through organic cash flow, enabling self-funded market initiatives without dilutive external financing.
Key to Novus's success is its dual-platform architecture that separates traditional healthcare services from cannabis commerce. Platform A functions as an online pharmacy and benefits platform handling 24,300 prescriptions and claims processing, while Platform B operates as a dedicated cannabis commerce platform connecting to a network of retailers. This separation ensures compliance with federal requirements while allowing the company to offer cannabis as a complementary benefit alongside traditional coverage.
The company's approach provides access to the substantial HSA/FSA market estimated at over $100 billion, creating what management describes as a first-mover advantage. By treating cannabis as a separate risk category and maintaining functional separation between healthcare and cannabis platforms, Novus establishes regulatory barriers that protect the core business from policy fluctuations while enabling growth independent of federal scheduling timelines.
Financial transparency remains a priority for the company, which maintains a simplified capital structure with no outstanding convertible notes and unchanged share count during the reporting period. The implementation of a Vendor Share Leak-Out Provision, capping vendor stock sales at 15% of the preceding 30-day average daily trading volume, aims to prevent undue selling pressure on the stock price. Management alignment is demonstrated through the absence of insider share sales over the past three years.
Novus's financial documents, including current and past filings, are accessible through the OTC Markets disclosure portal, providing investors with comprehensive information about the company's performance and strategy. The company's ability to achieve margin expansion while maintaining capital structure integrity suggests a sustainable growth model within the evolving cannabis healthcare landscape.
The results indicate growing acceptance of cannabis benefits within traditional healthcare frameworks and demonstrate how ancillary businesses can create economic value without direct involvement in cannabis cultivation or retail. As healthcare costs continue to rise nationally, Novus's model of integrating cannabis benefits with prescription drug plans represents an innovative approach to patient care that maintains regulatory compliance while addressing consumer demand for alternative treatment options.
